Clinical Strategies to Achieve an Early and Successful Response to Tyrosine Kinase Inhibitor Therapy

Seminars in Hematology

Volumn 46, Issue SUPPL. 3, 2009, Pages

  Hughes, Timothy ^a   Hochhaus, Andreas ^b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; ORGANIC CATION TRANSPORTER 1; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; LOW DRUG DOSE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN FUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; OCTAMER TRANSCRIPTION FACTOR-1; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 63249120081     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2009.01.008     Document Type: Article

References (23)

1. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108 (2006) 1809-1820
2. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348 (2003) 994-1004
3. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355 (2006) 2408-2417
4. Hughes T.P., Kaeda J., Branford S., Rudzki Z., Hochhaus A., Hensley M.L., et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349 (2003) 1423-1432
5. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. In press.
6. Guilhot F., Larson R.A., O'Brien S.G., Gathmann I., and Druker B.J. Time to complete cytogenetic response (CCyR) does not affect long-term outcomes for patients on imatinib therapy. Blood 110 (2007) 16a
7. Branford S., Seymour J.F., Grigg A., Arthur C., Lynch K., and Hughes T. Increasing frequency and marked stability of complete molecular response is observed in imatinib-treated CML patients with long-term follow up. Blood 108 (2006) 131a
8. Druker B.J., Gathmann I., Bolton A.E., and Larson R.A. Probability and impact of obtaining a cytogenetic response to imatinib as initial therapy for chronic myeloid leukemia (CML) in chronic phase. Blood 102 (2003) 182a
9. Aoki E., Kantarjian H., O'Brien S., Talpaz M., Giles F., Garcia-Manero G., et al. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. J Clin Oncol 24 (2006) 345s
10. Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Giles F., et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 103 (2004) 2873-2878
11. Baccarani M., Castagnetti F., and Porkka K. A prospective study of imatinib 400 mg vs 800 mg as a front-line therapy in Sokal high risk Ph+ chronic myeloid leukemia patients. Haematologica 93 Suppl 1 (2008) 161-162
12. Cortes J.E., Baccarani M., Guilhot F., Druker B.J., Yu R., Rudoltz M., et al. First report of the TOPS study: a randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Haematologica 93 Suppl 1 (2008) 160-161
13. Larson R.A., Druker B.J., Guilhot F.A., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
14. Picard S., Titier K., Etienne G., Teilhet E., Ducint D., Bernard M.A., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 109 (2007) 3496-3499
15. Thomas J., Wang L., Clark R.E., and Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104 (2004) 3739-3745
16. White D.L., Saunders V.A., Dang P., Engler J., Venables A., Zrim S., et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 110 (2007) 4064-4072
17. Kantarjian H.M., Talpaz M., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 101 (2003) 473-475
18. Kantarjian H., Pasquini R., Hamerschlak N., Rousselot P., Holowiecki J., Jootar S., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109 (2007) 5143-5150
19. Kantarjian H.M., Druker B.J., Guilhot F., Cortes J., O'Brien S.G., Krahnke T., et al. Imatinib dose escalation is effective in patients with chronic myeloid leukemia in chronic phase (CML-CP). Blood 110 (2007) 317a
20. Kantarjian H.M., Larson R.A., Guilhot F., O'Brien S.G., Mone M., Rudoltz M., et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 115 (2009) 551-560
21. Kantarjian H., Schiffer C., Jones D., and Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 111 (2008) 1774-1780
22. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108 (2006) 28-37
23. National Comprehensive Cancer Network. NCCN: Clinical practice guidelines in oncology. Chronic myelogenous leukemia (2009), 2006 National Comprehensive Cancer Network, Inc, Jenkintown, PA Version 2